ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again

 
• By Alaric DeArment
OS data from Gilead's TROPiCS-02 trial exceeded the expectations of many investors • Source: Shutterstock

More from Anticancer

More from Therapeutic Category